Sarepta Therapeutics, Inc. faces revenue decline, trial setbacks, and FDA decisions. Click for SRPT risks, outlook, and if ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.

Major U.S. equities indexes were lower at midday Tuesday, with Palantir Technologies leading tech stocks lower.

Despite disruptions and restructuring costs, Sarepta Therapeutics Inc (SRPT) showcases strong revenue performance and ...

Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid ...

Monday after the biotechnology company disclosed disappointing drug-trial data, which could lengthen the timeline of the ...

Sarepta Therapeutics' shares plunged nearly 40% in premarket trading on Tuesday as failure of two of its approved drugs for a ...

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock fell sharply Tuesday following disappointing results from a key clinical trial and ongoing concerns about its drug pipeline. However, "Pharma Bro" ...

Sarepta Therapeutics shares plunged 37% after two Duchenne muscular dystrophy drugs failed a key trial, raising regulatory ...

Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting ...

Shares in Sarepta Therapeutics lost nearly 40% of their value after the company said a trial designed to confirm the efficacy ...

Sarepta Therapeutics Inc. shares plunged after a trial designed to confirm the benefits of two of its older drugs failed to show clear patient improvement, raising questions about their future.